Outlook Therapeutics, Inc. (OTLK) 2018年年度报告「NASDAQ」.pdf

《Outlook Therapeutics, Inc. (OTLK) 2018年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Outlook Therapeutics, Inc. (OTLK) 2018年年度报告「NASDAQ」.pdf（206页珍藏版）》请在三个皮匠报告上搜索。

1、 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934ITEM 1.BusinessITEM 1A.Risk FactorsITEM 1B.Unresolved Staff CommentsITEM 2.PropertiesITEM 3.Legal ProceedingsITEM 4.Mine Safety

2、DisclosuresTABLE OF CONTENTSUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended September 30,2018ORFor the transition period from to Commission File Number:001-37759O

3、UTLOOK THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)Delaware38-3982704(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)7 Clarke Drive Cranbury,New Jersey 08512(609)619-3990(Address,including zip code,and telephone number,inclu

4、ding area code,of registrants principal executive offices)Securities registered pursuant to Section 12(b)of the Act:Title of Each ClassName of Each Exchange on Which RegisteredCommon Stock,$0.01 par value per shareThe Nasdaq Capital MarketSeries A warrants to purchase Common StockThe Nasdaq Capital

5、MarketSecurities Registered Pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.YesNoIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15

6、(d)of theAct.YesNoIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12 months(or for such shorter period than the registrant wasrequired to file such reports),and(2)has been subj